TSO3 Inc

TSO3 — Investor Presentation (March 2013)

36 slides from TSO3's investor presentation, March 2013

  1. Slide 1: Corporate Presentation

    Corporate Presentation Updated March 2013 (Y12 Results) Creating the Improved Standard in Healthcare Sterile Reprocessing

  2. Slide 2: Company Overview

    Company Overview • Founded 1998 • Designs and manufactures low temperature sterilizers for medical devices • IPO 2001 • TSX: TOS • 73M outstanding shares

  3. Slide 3: Historical Key Events

    Historical Key Events 1998 - 2008 • Initial sterilization platform (limitations in offering as per cycle times and compatibility) Regulatory clearance in Canada and the United States Sold directly by TSO3 with limited success (38 units/5 years) 2009-2010 • Renewed direction • Second generation steri

  4. Slide 4: Organizational Structure

    Organizational Structure President and CEO Customer Capture Innovation Management Supply Chain Quality and Retention Field Service Engineering Finance Procurement Customer Service Science HR Production IR / PR IT 4

  5. Slide 5: Our Vision

    Our Vision… To Create the Improved Standard in Healthcare Sterile Reprocessing

  6. Slide 6: Opportunity

    Opportunity Medical Sterile Reprocessing of Reusable Instruments 6

  7. Slide 7: Why low temperature sterilization?

    Why low temperature sterilization?

  8. Slide 8: Market Drivers

    Market Drivers 8

  9. Slide 9: Growing Population

    Growing Population 17% increase 7.9% increase 2010 2020 More people = more surgeries Annals of Surgery. 2003 August; 238(2): 170-177.

  10. Slide 10: Aging Population

    Aging Population 53% increase 65 yrs + 45 to 64 15 to 44 - 15 yrs 2001 2005 2010 2015 2020 65 yrs+ is the fastest growing segment Annals of Surgery. 2003 August; 238(2): 170-177.

  11. Slide 11: Impact of Age on Demand for Surgery

    Impact of Age on Demand for Surgery 88% of ophthalmology surgeries Number of 70% of cardiothoracic surgeries procedures (average) 65% of urology surgeries 60% of general surgeries Age 45 55 65 75 As we age, we require more OR time Annals of Surgery. 2003 August; 238(2): 170-177.

  12. Slide 12: Advancement in Medical Techniques

    Advancement in Medical Techniques From Traditional Open Surgery To Minimally Invasive Surgery (MIS) 12

  13. Slide 13: 30 million MIS Procedures

    MIS Procedures Increasingly used and finding new applications everyday Orthopaedic Neurosurgery Pulmonary medicine 30 million MIS Gynaecology surgeries in US/year Urology Gastrointestinal Cardiology 13 The National Institute of Health (NIH).

  14. Slide 14: MIS Devices are Complex and Delicate

    MIS Devices are Complex and Delicate $50k Colonoscope 14

  15. Slide 15: MIS Devices require low temperature sterilization

    MIS Devices require low temperature sterilization

  16. Slide 16: Sterilization Areas in Hospitals

    Sterilization Areas in Hospitals 2 OR 1 CS OR OR OR OR Central Sterilization (CS) Operating Room Department (OR) Low Temperature Sterilization OR OR OR OR Gas Liquid OR Reprocessing and Sterile Storage Steam Sterilization 3 GI Gastrointestinal Department (GI) Liquid 16

  17. Slide 17: Customers want Throughput

    Customers want THROUGHPUT TSO3 sterilizer conjoint study July 2009 - Allegheny Marketing Group.

  18. Slide 18: Low Temperature Sterile Reprocessing Solutions

    Low Temperature Sterile Reprocessing Solutions Ethylene Oxyde Hydrogen Peroxide Liquid Hydrogen Peroxide (EtO) (H2O2) Peracetic Acid (PAA) + Ozone (H2O2/O3) Efficacious Fast Specific use in OR Fast High material Limited in Liquid = Not terminal Efficacious compatibility efficacy sterilization Long c

  19. Slide 19: Our Technology Enables Throughput

    Our Technology Enables Throughput By combining: • Efficacy and compatibility • High loading capacity • Speed 19

  20. Slide 20: Customer Feedback

    Customer Feedback • “Improving our standard of care by terminally sterilizing devices previously reprocessed using a liquid chemical sterilization method” • “Virtually eliminated the use of the liquid process, as flexible scopes are now terminally sterilized, along with additional devices” • “Runnin

  21. Slide 21: Global Market Overview / Low Temperature Sterilization

    Global Market Overview / Low Temperature Sterilization* • Capital equipment business – Low temperature gas sterilizers in Worldwide Installed Base hospitals: • ~30,000 installed worldwide • Life span ~ 10 years • Replacement business: 3,000 units/year US Canada • Consummables business Europe – Estim

  22. Slide 22: Revenues on Unit Sale over 10-year

    Revenues on Unit Sale over 10-year End-user Price $ 640k $480k $320k Margins $160k 1 2 3 4 5 6 7 8 9 10 Year 22

  23. Slide 23: Channel Partnership

    Channel Partnership • Signed agreement with 3M in December 2009 for the exclusive supply, distribution, license and service of the new STERIZONE® 125L+ Sterilizer; • Amended agreement in May 2011 to include new sterilizer intended for the OR Substerile Area in hospitals (STERIZONE® 80L Sterilizer);

  24. Slide 24: Activities Status

    Activities Status 24

  25. Slide 25: Key Strategic Activities

    Key Strategic Activities • Regulatory – Focused on US 510(k) clearance for the STERIZONE® 125L+ Sterilizer • Commercial – Bringing home the right partnership agreement • Porfolio – Completing development and filing the STERIZONE® 80L Sterilizer • 3M – Settle dispute 25

  26. Slide 26: Regulatory Status USA

    Regulatory Status USA • New simplified approach – Filed January 28, 2013 – Single cycle (one set of parameters/one set of monitoring) – Increased claims – Intact value proposition • Shortened US regulatory process – Total process time as per FDA guidelines = 270 days – Passed acceptance review (admi

  27. Slide 27: What is moving through the US Regulatory Process from TSO3?

    What is moving through the US Regulatory Process from TSO3? Biological Indicator (BI) Process Indicator (CI) Test Pack Sterile Efficacy Validation Sterilizer 27

  28. Slide 28: Current Negotiations

    Current Negotiations Home | Services | Beyond the Wire | About CNW Register / Login | Francais Cc IN W FINANCIALS WEBCASTS EVENTS CANADA NEWSWIRE S&P/TSX Comp 11835.10 ¥ -23.03 (-0.19) S&P/TSXV Comp 1190.54 ¥ -2.51(-0.21) | DJIA 13165.19 wv -10.45 (-0.08) MORE FINANCIALS ¥ Ai 7, 2012 1:50 PM - Fi: i

  29. Slide 29: Preferred Partnership

    Preferred Partnership • Global in scope • Reputation and credibility at end-user level • Experience in capital sales • Direct experience in after-sales service • Mutually beneficial – Market reach for TSO3 with commitments – Bolt-on product/technology to existing offering for channel partner • Refle

  30. Slide 30: Next product: the STERIZONE 80L Sterilizer

    Next product: the STERIZONE® 80L Sterilizer • Approach is to secure 125L+ US clearance for subsequent international filing on the 80L. • Targeting initial commercial event late 2013, early 2014. • Market : OR Substerile Area • Inventory limitations, flexibility in schedule, shorter turnaround time •

  31. Slide 31: Our Positioning

    Our Positioning f 31

  32. Slide 32: Our Strengths

    Our Strengths • Rapid research and prototyping – Small and flexible structure – Tunable technology • Sterilization testing expertise – Microbiology – Materials compatibility testing • Positive regulatory track record • Licensing-out 32

  33. Slide 33: What to expect in the next 12 months?

    What to expect in the next 12 months ? • Obtain United States regulatory clearance for the STERIZONE® 125L+ Sterilizer • Subsequent completion of STERIZONE® 80L Sterilizer development and filing for clearances (Health Canada, CE Mark and Food and Drug Administration) • Secure the right channel partn

  34. Slide 34: Financial Situation – As of Dec. 31

    Financial Situation – As of Dec. 31 Dec 2012 (000’s) Total Sales Revenue – last 12 months 1,162,922 Cash, Cash Equivalents and Temporary Investments 12,807,190 Inventories 1,216,721 Total Assets 19,435,477 Equity 18,427,493 Monthly Burn Rate 735,737* Outstanding Shares 65,888,182 Outstanding Options

  35. Slide 35: Investment Highlights

    Investment Highlights • Large and growing market • Superior technology meets customer needs pending • FDA approval representing 40% of worldwide market • In discussions with strong global channel partner • Pursuing new applications and opportunities • Financially sound 35

  36. Slide 36: © TSO3 Inc., 2013

    © TSO3 Inc., 2013. All rights reserved. No part of this publication may be reproduced or translated in any form or by any means, without the prior written permission of TSO3 Inc. - OZO-TEST® - STERIZONE® are Reg. U.S. Pat. & Tm. Off. TSO3 STERIZONE® Sterilizer U.S. Pat. No. 7,128,872 / 7,582,257 / 7

TSO3 — Investor Presentation (March 2013) on 6ix